Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight

November 9, 2017 4:37 AM EST

JPMorgan upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $162.00 (from $86.00).

Analyst Anupam Rama believes givosiran remains underappreciated on the Street and as a driver of upside for the company. The analyst also is expecting a smooth... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'

November 8, 2017 11:54 AM EST

Barclays raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $158.00 (from $127.00) while maintaining a Overweight rating, following the company's third quarter earnings report.

Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share results above... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel

November 8, 2017 10:07 AM EST

Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.

Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.

... More